When magnetic nanoparticles (MNPs) are used as a contrast agent for magnetic particle imaging (MPI), they are rapidly excreted during systemic circulation by the reticuloendothelial system such as Kupffer cells in the liver. Therefore, when considering clinical applications of MPI such as long-term monitoring of cardiovascular diseases, increasing the blood circulation time of MNPs by encapsulating the MNPs into actual cells such as red blood cells (RBCs) as a carrier may be practical. The purpose of this study was to create a biocompatible tracer for MPI by encapsulating MNPs (Resovist ® ) into RBCs, and to investigate the effect of the encapsulating procedure on the properties of the RBCs loaded with MNPs (L-RBCs). MNPs were encapsulated into RBCs by the hypotonic dialysis method using a hypotonic buffer solution at three different osmotic pressures. Transmission (TEM) and scanning electron microscopic (SEM) images of the L-RBCs were obtained, and the saturation magnetic moment (Ms) was measured using vibrating sample magnetometry (VSM) . From the response to a permanent magnet, the findings on TEM images, and the Ms values measured by VSM, we confirmed that RBCs were successfully loaded with MNPs using the hypotonic dialysis method. When the osmotic pressure was 80 mOsm, MNPs were not retained sufficiently inside the RBCs but were adhered to the membrane surface (TEM images), and RBCs lost their biconcave disc shape and shrunk after resealing (SEM images). At 160 mOsm, the Ms value was much lower than those at 80 and 120 mOsm. At 120 mOsm, the shape of RBCs was preserved (SEM images) and the Ms value was the highest when 0.2 ml (5.6 mg of Fe) of Resovist ® was added to the dialysis tube for loading. In conclusion, we successfully encapsulated MNPs into RBCs using the hypotonic dialysis method. Our results suggest that an osmotic pressure of 120 mOsm is optimal for encapsulating MNPs into RBCs using the hypotonic dialysis method.
Introduction
Encapsulation of drugs in a drug delivery system (DDS) is useful to reduce the toxicity of the drugs, to increase the biocompatibility, and to protect the drugs from degradation. Micrometer-scale DDS such as microcapsules and liposomes have been constructed z1|. However, the surfaces of these chemosynthetic carriers are different from the lipid and protein of a cell membrane. These differences lead to recognition by macrophages and undesirable removal by the reticuloendothelial system (RES) such as Kupffer cells in the liver. Therefore, the use of actual cells as a carrier for drug encapsulation is necessaryz1|.
In cell-based DDS, the red blood cell (RBC) is one of the most promising carriers for drug encapsulation. RBCs have several advantages over other drug carriers. For example, they are highly biocompatible and completely biodegradable without generating toxic products, and most of their volume is available for encapsulation of drugs z1, 2|. Several methods have been proposed to encapsulate therapeutic agents into RBCs. Of these methods, the hypotonic dialysis method is the best, because it preserves the biochemical, immunological, and physiological properties of native RBCs after encapsulationz1, 2|. In this method, RBCs are placed in a dialysis tube and then immersed in a hypotonic solution. During incubation, membrane pores appear and open, during which a drug added externally can be incorporated into the RBCs by a passive mechanism. Finally, by raising the salt concentration to an isotonic level, the pores close and the drug remains encapsulated inside the RBCs z1, 3|. Recently, a new imaging method called magnetic particle imaging (MPI) has been introduced z8|, which allows imaging of the spatial distribution of MNPs such as superparamagnetic iron oxide with high sensitivity, high spatial resolution, and high imaging speed. Thus, MPI is considered to be a promising imaging modality in the field of molecular imaging. MPI uses the nonlinear response of MNPs to detect their presence in an oscillating magnetic field called the drive magnetic field (DMF). Spatial encoding is realized by saturating the MNPs almost everywhere except in the vicinity of a special point called the field-free point (FFP) using a static magnetic field (SMF) z8, 9|. Recently, we have also constructed an apparatus for MPI in which both DMF and SMF are generated using a Maxwell coil pairz10|. In our apparatus, the peak-to-peak strength of the DMF was taken as approximately 16 to 24 kA/m, while the gradient of the SMF as approximately 800 to 1200 kA/m 2 z10|. When MNPs are used as a contrast agent for MPI, they are rapidly removed from the blood stream by the RES as mentioned above. Therefore, the application of MPI for long-term monitoring of systemic circulation requires repeated administration of MNPs, which complicates quantitative comparisons due to the temporal variations in concentration z11|. In order to overcome these drawbacks, it appears to be necessary to increase the blood circulation time of MNPs by encapsulating the MNPs into actual cells such as RBCs as a carrier. Because L-RBCs appear to be more biocompatible than conventional MNPs, they will be useful as a potential contrast agent for new applications of MPI to the diagnosis and/or longterm monitoring of cardiovascular diseasesz12|.
During encapsulation of MNPs into RBCs, the RBCs are exposed to conditions very different from the physiological state. Such an environment may cause damage to the cell membrane, possibly leading to recognition by macrophages and undesirable removal by the RES, and consequently decreasing the useful lifetime of L-RBCs z13, 14|, decreasing the sensitivity of imaging, and/or increasing the dosage of contrast agent z15|. It is thus important to investigate the optimal conditions for encapsulating MNPs into RBCs. To the best of our knowledge, such studies have not been performed extensively. The purpose of this study was to create a biocompatible tracer for MPI by encapsulating MNPs into RBCs, and to investigate the effects of the encapsulating procedure, especially the osmotic pressure of the hypotonic buffer solution, on the properties of L-RBCs.
Materials and Methods

Magnetic nanoparticles and phosphate buffered
saline solution In this study, we used Resovist ® (Fujifilm RI Pharma Co., Ltd., Tokyo, Japan) as MNPs. Resovist ® consists of superparamagnetic and polycrystalline iron oxide (SPIO) (maghemite, γ-Fe2 O3) coated with carboxydextran z16|. Phosphate buffered saline solution (PBS)(NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM and KH2PO4 2 mM, pH 7.4) was prepared from a 10-fold PBS stock solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Encapsulation of magnetic nanoparticles into red
blood cells Whole blood of sheep was purchased from Kohjin Bio Co., Ltd. (Saitama, Japan). RBCs were obtained by centrifuging the whole blood at 2000 g for 10 min at 4ºC, and removing the plasma and buffy coat. They were washed twice in PBS at 4ºC and suspended in PBS to 50％ hematocrit. A dialysis tube with a molecular weight cutoff of 12-14 kDa (UC20-32-100, Eidia Co., Ltd., Tokyo, Japan) filled with 0.15 ml (4.2 mg of Fe) or 0.20 ml (5.6 mg of Fe) of Resovist ® and 1 ml of RBCs was dialyzed for 75 min at room temperature with agitation in 50 ml dialysis buffer solution (KCl 0.14 mM, Na2HPO4 0.5 mM, KH2PO4 0.1 mM, glucose 20 mM, MgCl2 4 mM, NaHCO3 10 mM, ATP 1 mM, and reduced glutathione 3 mM). NaCl was added to the dialysis buffer solution to adjust the osmotic pressure. In this study, osmotic pressures at 80, 120, and 160 mOsm were examined. Resealing of RBCs was performed by adding a resealing buffer solution (NaCl 200 mM, KCl 1600 mM, Na2HPO4 10 mM, KH2PO4 1.8 mM, glucose 100 mM, MgCl2 4 mM, pyruvate 100 mM, adenine 5 mM, inosine 100 mM, and ATP 1 mM) until the external solution became isotonic or slightly hypertonic. The resealed RBCs were incubated for 45 min at 37ºC. The RBCs were washed four times in PBS at 4ºC to remove excess Resovist ® and other molecules not taken up by RBCs, and stored in PBS.
Transmission electron microscopy
For transmission electron microscopy (TEM) analysis, the RBCs were fixed in 2％ glutaraldehyde for 1 h and postfixed in 1％ tetroxide osmium (OsO4) for 2 h. They were then dehydrated with ethanol and embedded in resins. Thin sections of the resin blocks were prepared and collected onto nickel grids. The sections were observed under a transmission electron microscope (H-7650, Hitachi Co., Ltd., Tokyo, Japan).
Scanning electron microscopy
For scanning electron microscopy (SEM) analysis, RBCs were fixed in 2％ glutaraldehyde and the suspension was dropped on a glass slide. The glass slide was washed twice, postfixed in 1％ OsO4 for 2 h, and dehydrated with ethanol. The glass slide was coated with OsO4 and then observed under a scanning electron microscope (S-4800, Hitachi Co., Ltd., Tokyo, Japan).
Vibrating sample magnetometry
Vibrating sample magnetometry (VSM) (VSM-HT80, Riken Denshi Co., Ltd., Tokyo, Japan) was used to measure the magnetic moment of L-RBCs. A sample Advanced Biomedical Engineering. Vol. 4, 2014. (approximately 20 μl) of L-RBCs was dropped on an amber glass base and dried in a vacuum. The dried sample was fixed to the sample stand, and the magnetic moment was produced by vibrating the sample in a static magnetic field that was varied from −1200 to 1200 kA/m. The magnetic moment was corrected by the mass of the sample.
Simulation studies 2.6.1 Langevin function
The magnetization of MNPs in response to an applied magnetic field can be described by the Langevin function z17|given by :
where M0 is the saturation magnetization and ξ is the ratio between the magnetic energy of a particle with magnetic moment m in an external magnetic field H. The thermal energy is given by the Boltzmann constant kB and the absolute temperature T : ξ=μmH /T=μMVH /T.
( 2 ) In Eq.2, Md is the domain magnetization of a suspended particle and VM is the magnetic volume given by V=πD  /6 for a particle of diameter D. It is well known that when ξ approaches zero in Eq. 1, M(ξ) can be approximated byz17| :
Therefore, the initial slope of the plot between M(ξ) and H, called the initial magnetic susceptibility (ΧL), is given byz18| :
Particle size distribution
Because not all particles in a given volume have the same diameter D, the magnetization of MNPs with diameter D zM(D)| should be averaged based on the particle size distribution as :
where ρ(D) denotes the probability density function of the particle size distribution. The result of a natural growth process during particle synthesis does not yield particles with a single diameter D, but particles with a polydisperse particle size distribution z19|. A reasonable and commonly used approach for modeling is the log-normal distribution z19|. The probability density function of the particle size distribution ρ(D) is given by :
where μ (mean of log-normal distribution) and σ (standard deviation (SD) of log-normal distribution) are given by :
and
respectively. E(D) and  Var(D) denote the mean and SD of D, respectively. In this study, we considered maghemite (γ-Fe2O3) as MNPs, and Md in Eq. 2 was taken as 414 kA/mz20|. The temperature and the coefficient of viscosity were assumed to be 20ºC (293.15 K) and 0.007 Pas, respectively, in all simulation studies. σ given by Eq. 8 was fixed at 0.209z21|. Figure 1a shows the photograph when L-RBCs under an osmotic pressure of 120 mOsm were brought close to a permanent magnet (Neodymium magnet, Magfine Co., Sendai, Japan), and pressure was 80 mOsm, MNPs appeared to be adhered to the membrane of RBCs (Fig. 2c) . No MNPs were observed in N-RBCs (Fig. 2a) and ND-RBCs (Fig. 2b) . (Fig. 3c) . At the osmotic pressure of 120 mOsm, although some changes were observed on the membrane of RBCs, the shape was maintained and the size was approximately the same as that of N-RBCs and ND-RBCs (Fig. 3d) . At 160 mOsm, the RBCs seemed to be swollen compared to N-RBCs and ND-RBCs (Fig. 3e) . Figure 4 shows the magnetization curves measured by VSM for L-RBCs under 80 mOsm, 120 mOsm, and 160 mOsm, and for N-RBCs, and ND-RBCs. The amounts of Resovist ® used in the dialysis tube for loading were 0.15 ml (4.2 mg of Fe) (Fig. 4a) and 0.20 ml (5.6 mg of Fe) (Fig. 4b) . The L-RBCs showed a nonlinear magnetization response to the external magnetic field, whereas N-RBCs and ND-RBCs showed no magnetization response. The nonlinear magnetization responses differed depending on the osmotic pressure of the dialysis buffer solution, and the saturation magnetic moment was dependent on the osmotic pressure. The saturation magnetic moment at 160 mOsm was lower than that at 80 mOsm or 120 mOsm (Fig. 4) . Furthermore, it is obvious from the comparison between Figs. 4a and 4b that the saturation magnetic moment was higher when 0.20 ml Resovist ® was used in loading compared to 0.15 ml. In order to investigate whether hysteresis and residual magnetization exist in magnetization curves, we show the normalized magnetization curves for the magnetic field ranging from −50 to 50 kA/m in Fig. 6 . Although some hysteresis and residual magnetization were observed, they were much smaller than those of ferromagnetic nanoparticles z21|. These findings are consistent with the fact that the MNPs used in this study are superparamagneticz21|. Figure 7 shows the simulation results. Figure 7a shows the probability density function given by Eq. 4 as a function of the diameter of MNPs for various mean diameters (6, 8, 10, and 15 nm), and Fig. 7b shows the normalized magnetic moment as a function of magnetic field for various mean diameters (6, 8, 10, and 15 nm) . The magnetic moment depends on the mean diameter of MNPs, and saturates at a lower magnetic field strength as 
Results
Advanced Biomedical Engineering. Vol. 4, 2014.
Discussion
In this study, to create a biocompatible tracer for MPI, we attempted to encapsulate MNPs (Resovist ® ) into RBCs by the hypotonic dialysis method using a hypotonic buffer solution at three different osmotic pressures.From the response to a permanent magnet (Fig. 1) , the findings on TEM images (Fig. 2) , and the magnetic moment measurement by VSM (Fig. 4) we confirmed that the RBCs were successfully loaded with MNPs using the hypotonic dialysis method.
As shown in Fig. 4 , the saturation magnetic moment of L-RBCs depended on the osmotic pressure of the hypotonic buffer solution. When the osmotic pressure was 160 mOsm, the saturation magnetization was clearly lower than that at 80 or 120 mOsm. This may be due to a smaller number of pores that opened on the membrane during hypotonic dialysis at 160 mOsm compared to lower osmotic pressures, and/or insufficient opening of the pores due to the higher osmotic pressure. When the osmotic pressure was 80 mOsm, MNPs were not retained inside the RBCs but adhered on the membrane surface (Fig. 2c) . Furthermore, the RBCs lost their biconcave disc shape and shrunk after resealing (Fig. 3c) . Because these morphological changes may reduce the lifetime of tracers in vivo as described above, dialysis using an excessively hypotonic buffer solution will not be suitable for making these tracers. Therefore, our results suggest that 120 mOsm is the optimal osmotic pressure for hypotonic dialysis. Furthermore, the magnetic moment of L-RBCs increased with increasing concentration of the MNPs added to the dialysis tube ( Fig. 4a and b) . Thus, it is possible to increase the sensitivity of the L-RBCs when used as a contrast agent in MPI by increasing the concentration of the MNPs added to the dialysis.
As shown in Fig. 5 , there was a difference in the magnetization curve between L-RBCs and bulk Resovist ® . The L-RBCs tended to saturate at a lower magnetic field strength than the bulk Resovist ® . It is well known that because MNPs are not monodispersed, the magnetic moment depends mainly on the particle size distribution of MNPsz22|. As mentioned by Pierige et al.z1|, when the RBCs are placed in a hypotonic solution, they can reach a critical hemolytic volume giving rise to holes on the membrane ranging from 10 nm to 500 nm. Thus, the findings shown in Fig. 5 may be due to changes in particle size distribution of MNPs in RBCs as a result of the MNPs moving through these holes during hypotonic dialysis and resealing. On the other hand, Markov et al. z12|reported that RBCs loaded with MNPs tend to exhibit magnetization saturation at a greater magnetic field strength compared to the bulk tracers. Their findings are in conflict with our results (Fig. 5) . Furthermore, they explained their results by a reduction in the average size of the nanoparticles upon encapsulation. As shown in our Yuki simulation results (Fig. 7b) , the magnetic moment saturates at a lower magnetic field strength with increasing mean diameter of MNPs. This can be verified from Eq. 4, because the initial slope of the plot between M (ξ) and H is approximately proportional to VM. Thus, in contrast to the explanation given by Markov et al.z12|, we consider that the particle size distribution shifted to a larger average value. Thus, we consider that smaller particles are more likely to exit from the RBCs during resealing than larger particles, and therefore larger particles are more likely to retained inside the RBCs than smaller ones. Further studies are necessary to elucidate the reason for the discrepancy between our findings and the results reported by Markov et al.z12|.
Although we investigated the morphological change of RBCs after encapsulation using SEM (Fig. 3) in this study, we did not quantitatively investigate the RBC membrane damage due to the loading procedures. RBCs are exposed to conditions very different from the physiological state during the loading procedures, and damage to the RBC membrane may be expected. Such membrane damage may significantly affect the lifetime of the L-RBCs. Further studies are necessary to quantitatively evaluate the membrane damage of RBCs after encapsulation of MNPs, using methods such as flow cytometry and confocal microscopy. These studies will be performed in the near future.
Conclusion
We successfully encapsulated MNPs into RBCs using the hypotonic dialysis method, as a potential contrast agent for MPI. Our results demonstrated that the properties of L-RBCs are dependent on the osmotic pressure of the hypotonic buffer solution, and suggest that 120 mOsm is the optimal osmotic pressure for encapsulating MNPs into RBCs using the hypotonic dialysis method. 
